Defence Therapeutics' AccuTOX Study Published in Journal of Translational Medicine

Vancouver-based Defence Therapeutics Inc. has announced the publication of a peer-reviewed study on its anti-cancer molecule AccuTOX®. The study, "Local delivery of AccuTOX® synergises with immune-checkpoint inhibitors at disrupting tumor growth," appears in the Journal of Translational Medicine.

AccuTOX® is derived from the Accum® platform, initially designed to deliver biomedicines to target cells. AccuTOX® shows enhanced cancer cell killing ability, ease of manufacturing, and can serve as a cleavable anticancer molecule linked to antibodies.

The study highlights AccuTOX®'s superior therapeutic properties compared to its parent molecule Accum®. It induces cell death in various cancer cell lines, enhances immune system visibility of cancer cells, and works synergistically with immune-checkpoint inhibitors to control tumor growth.

Defence Therapeutics plans to expand clinical testing with an FDA-approved Phase I trial and recently submitted a CTA application to Health Canada.